DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDA) is one of the most aggressive malignancies in humans, and its prognosis is generally poor even after surgery. Many advances have been made to understand the pathogenesis of PDA; however, the molecular mechanisms that lead to pancreatic carcinogenesis are still...

Full description

Saved in:
Bibliographic Details
Published in:Tumor biology 2013-10, Vol.34 (5), p.2857-2861
Main Authors: Xue, Yu-Zheng, Wu, Tie-Long, Wu, Yan-Min, Sheng, Ying-Yue, Wei, Zhe-Qiang, Lu, Yu-Feng, Yu, Li-Hua, Li, Jian-Ping, Li, Zhao-Shen
Format: Article
Language:English
Subjects:
Adult
Aged
Biomarkers
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Biomedical and Life Sciences
Biomedicine
Cancer Research
Carcinoma, Pancreatic Ductal - genetics
Carcinoma, Pancreatic Ductal - metabolism
Carcinoma, Pancreatic Ductal - mortality
DNA Methylation
Down-Regulation
Female
Gene Expression
Gene Expression Regulation, Neoplastic
Genes
GTPase-Activating Proteins - genetics
GTPase-Activating Proteins - metabolism
Humans
Kaplan-Meier Estimate
Male
Medical prognosis
Middle Aged
Multivariate Analysis
Pancreas - metabolism
Pancreatic cancer
Pancreatic Neoplasms - genetics
Pancreatic Neoplasms - metabolism
Pancreatic Neoplasms - mortality
Prognosis
Promoter Regions, Genetic
Research Article
RNA, Messenger - genetics
RNA, Messenger - metabolism
Tumor Suppressor Proteins - genetics
Tumor Suppressor Proteins - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pancreatic ductal adenocarcinoma (PDA) is one of the most aggressive malignancies in humans, and its prognosis is generally poor even after surgery. Many advances have been made to understand the pathogenesis of PDA; however, the molecular mechanisms that lead to pancreatic carcinogenesis are still not clearly understood. The aims of this study were to investigate the relationship between DLC-1 methylation status and clinicopathological characteristics of PDA patients and evaluate the role of DLC-1 methylation status in PDA. The expression of DLC-1 mRNA in PDA tissues was analyzed by real-time PCR. The methylation status of DLC-1 was analyzed by methylation-specific polymerase chain reaction (MSP). Furthermore, we determined the prognostic importance of DLC-1 methylation status in PDA patients. Our results showed that the expression level of DLC-1 mRNA in PDA tissues was lower than that in non-cancerous tissues. The rate of DLC-1 promoter methylation was significantly higher in PDA tissues than in adjacent non-cancerous tissues ( p  
ISSN:1010-4283
1423-0380
DOI:10.1007/s13277-013-0846-4